Company profile: ReNeuron
1.1 - Company Overview
Company description
- Provider of stem cell-based exosome technologies and cell therapy programs. Offers the CustomEx platform for customizable exosomes delivering nucleic acids, proteins and gene editing; a conditionally immortalized iPSC platform for allogeneic cell lines and exosome production with specific tissue targeting; and hRPC for retinitis pigmentosa and CTX for stroke-induced disabilities, available for out-license outside of China.
Products and services
- Conditionally immortalized Induced Pluripotent Stem cell (iPSC) platform: Modular engine enabling rapid development of new allogeneic cell lines for cell-based therapeutics or producing exosomes with specific tissue targeting using conditional immortalization
- CustomEx Exosome Technology Platform: Custom-engineered platform that architects customizable exosomes for targeted delivery of nucleic acids, proteins, and gene editing technologies, enabling payload-specific tissue targeting for precision payload transport
- HRPC Program in Retinitis Pigmentosa: Clinical-stage program employing human retinal progenitor cells to treat retinitis pigmentosa, offered for out-licensing outside China, emphasizing cell-based intervention in ocular degeneration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ReNeuron
ADx Neurosciences
HQ: Belgium
Website
- Description: Provider of proprietary biomarker assays and antibody solutions for neurodegenerative diseases, enabling early detection of Alzheimer’s, Parkinson’s and traumatic brain injury. Delivers custom and monoclonal antibodies (Amyloid-beta, Tau, Synuclein), pharma and IVD solutions from antibody to qualified assay and automated kits, and co-develops commercial immunoassays for clinical and drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADx Neurosciences company profile →
MapLight Therapeutics
HQ: United States
Website
- Description: Provider of a discovery platform using optogenetics, STARmap, and transcriptomics to identify neural circuits and develop therapeutics for brain disorders, including ML-004 for Autism Spectrum Disorder (Phase 2), and candidates for schizophrenia (M1/M4 muscarinic), Alzheimer’s disease psychosis, and Parkinson’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MapLight Therapeutics company profile →
MyndTec
HQ: Canada
Website
- Description: Provider of medical devices focused on the treatment of stroke, spinal cord injury (SCI), and other brain-related disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MyndTec company profile →
Freespira
HQ: United States
Website
- Description: Provider of the only FDA-cleared, at-home, drug-free digital therapeutic proven to significantly reduce or eliminate panic attacks, panic disorder, and PTSD symptoms in 28 days. The Freespira treatment uses a sensor and tablet to normalize breathing. Also offers resources for health plans, employees, and individuals, a veterans relief program, and a provider referral program with insurance coverage information.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Freespira company profile →
Anavex Life Sciences
HQ: United States
Website
- Description: Provider of biopharmaceutical drug candidates for cancer and neurological diseases, including ANAVEX 2-73 (blarcamesine), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) for Alzheimer's, Parkinson's, and Rett syndrome; ANAVEX 3-71 targeting sigma-1 and M1 muscarinic receptors for schizophrenia, Alzheimer's, and frontotemporal dementia; and the SIGMACEPTOR Discovery Platform for CNS disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anavex Life Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ReNeuron
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ReNeuron
2.2 - Growth funds investing in similar companies to ReNeuron
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ReNeuron
4.2 - Public trading comparable groups for ReNeuron
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →